- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adaptimmune Therapeutics Plc (ADAP)
Adaptimmune Therapeutics Plc stock price live, this page displays NASDAQ ADAP stock exchange data. View the ADAP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adaptimmune Therapeutics Plc real time stock price chart below.
What Is the Adaptimmune Therapeutics Plc Stock Price Today?
The Adaptimmune Therapeutics Plc stock price today is 0.242.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc?
The stock ticker symbol for Adaptimmune Therapeutics Plc is ADAP.
Is ADAP the Same as $ADAP?
$ADAP is a common way to refer to the Adaptimmune Therapeutics Plc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Adaptimmune Therapeutics Plc Trade On?
Adaptimmune Therapeutics Plc is listed and trades on the NASDAQ stock exchange.
Is Adaptimmune Therapeutics Plc a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Adaptimmune Therapeutics Plc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAP quote. (ISIN: US00653A1079)
What Is the Adaptimmune Therapeutics Plc Stock Price Today?
The Adaptimmune Therapeutics Plc stock price today is 0.242.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc?
The stock ticker symbol for Adaptimmune Therapeutics Plc is ADAP.
Is ADAP the Same as $ADAP?
$ADAP is a common way to refer to the Adaptimmune Therapeutics Plc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Adaptimmune Therapeutics Plc Trade On?
Adaptimmune Therapeutics Plc is listed and trades on the NASDAQ stock exchange.
Is Adaptimmune Therapeutics Plc a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Adaptimmune Therapeutics Plc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAP quote. (ISIN: US00653A1079)
0.242
-0.004(-1.63%)
Closed·
After Hours
0.257+0.015(+6.198%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.240
0.260
52 wk Range
0.195
1.480
ADAP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2400.260
52 wk Range
0.1951.480
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADAP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
1.576
Upside
+551.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Adaptimmune Therapeutics Plc Company Profile
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics Plc SWOT Analysis
Market Challenges | Delve into Adaptimmune's strategy to navigate high therapy costs, market adoption hurdles, and fierce competition in the evolving cell therapy landscape |
Pipeline Potential | Explore Adaptimmune's promising candidates beyond Tecelra, including Lete-cel with pivotal data expected in late 2024 |
Financial Crossroads | Despite 146% revenue growth, Adaptimmune faces negative EPS forecasts and a shortened cash runway, presenting a complex financial outlook |
TCR-T Pionee | Adaptimmune leads with early FDA approval of Tecelra for synovial sarcoma, marking its transition to a commercial-stage biotech company |
Adaptimmune Therapeutics Plc Earnings Call Summary for Q4/2024
- Q4 2024 product revenue at $1.2M; targeting $25M sales in 2025 with 3-4x revenue increase expected in Q1 2025
- Stock fell 4.01% premarket despite 146% revenue growth in last 12 months; market cap at $115M suggests potential undervaluation
- Strategic cost reductions aim to save $75-100M over 4 years; company targets profitability by 2027
- TCELLRA launch successful with 20 treatment centers; plans to expand to 30 by end of 2025
- CEO optimistic about sales acceleration; exploring partnerships and monetization opportunities for future growth
Last Updated: 03/20/2025, 09:11 AM
Read Full TranscriptCompare ADAP to Peers and Sector
Metrics to compare | ADAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −2.0x | −0.5x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price / Book | −1.7x | 0.5x | 2.6x | |
Price / LTM Sales | 0.4x | 5.2x | 3.1x | |
Upside (Analyst Target) | - | 371.7% | 51.1% | |
Fair Value Upside | Unlock | 42.6% | 8.9% | Unlock |
Analyst Ratings
5 Buy
3 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1.576
(+551.34% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.03 / -0.12
Revenue / Forecast
7.29M / 7.55M
People Also Watch
FAQ
What Is the Adaptimmune Therapeutics (ADAP) Stock Price Today?
The Adaptimmune Therapeutics stock price today is 0.24
What Stock Exchange Does Adaptimmune Therapeutics Trade On?
Adaptimmune Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Adaptimmune Therapeutics?
The stock symbol for Adaptimmune Therapeutics is "ADAP."
What Is the Adaptimmune Therapeutics Market Cap?
As of today, Adaptimmune Therapeutics market cap is 64.22M.
What Is Adaptimmune Therapeutics's Earnings Per Share (TTM)?
The Adaptimmune Therapeutics EPS (TTM) is -0.27.
When Is the Next Adaptimmune Therapeutics Earnings Date?
Adaptimmune Therapeutics will release its next earnings report on Aug 06, 2025.
From a Technical Analysis Perspective, Is ADAP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Adaptimmune Therapeutics Stock Split?
Adaptimmune Therapeutics has split 0 times.
How Many Employees Does Adaptimmune Therapeutics Have?
Adaptimmune Therapeutics has 506 employees.
What is the current trading status of Adaptimmune Therapeutics (ADAP)?
As of Jun 16, 2025, Adaptimmune Therapeutics (ADAP) is trading at a price of 0.24, with a previous close of 0.25. The stock has fluctuated within a day range of 0.24 to 0.26, while its 52-week range spans from 0.20 to 1.48.
What Is Adaptimmune Therapeutics (ADAP) Price Target According to Analysts?
The average 12-month price target for Adaptimmune Therapeutics is USD1.57625, with a high estimate of USD3 and a low estimate of USD0.46. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +551.34% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.